What changed
Anavex Life Sciences received confirmation from Nasdaq that it has regained compliance with Listing Rule 5250(c)(1). The Company filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 on August 28, 2026. Its common stock will continue to trade on the Nasdaq Global Select Market under ticker AVXL.